An International Observational Prospective Study On Long-Term Response To Botulinum Toxin Type A (BoNT-A) Injections In Subjects Suffering From Idiopathic Cervical Dystonia (CD) - Pharmaco-Economic Impact
Latest Information Update: 06 Nov 2020
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Torticollis
- Focus Therapeutic Use
- Acronyms INTEREST IN CD2
- Sponsors Ipsen
- 16 Sep 2020 Results of metaanalysis of three observational studies (INTEREST IN CD1, INTEREST IN CD2 and ANCHOR CD) evaluating the effect of abobotulinumtoxinA on pain associated with cervical dystonia presented at the 24th International Congress of Parkinson's Disease and Movement Disorders
- 01 May 2020 Results (N=337), post hoc analysis of subjects treated with aboBoNT-A assessing Satisfaction outcomes , presented at the 72nd Annual Meeting of the American Academy of Neurology
- 09 Oct 2018 Results from INTEREST IN CD1 [NCT00833196] INTER- EST IN CD2 [NCT01753349] and ANCHOR-CD [NCT01314365] describing the use of injection guidance (at baseline/ first injection visit and at 1 year) in 585 subjects, presented at the 22nd International Congress of Parkinson's Disease and Movement Disorders.